{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260327314744/en/Lebrikizumab-delivered-long-term-disease-control-for-up-to-four-years-in-patients-with-moderate-to-severe-atopic-dermatitis", "message": "News view counter 629006 successfully enlarged"}